Home > Browse Research > Life Sciences > Pharmaceuticals > Research & Development

Research & Development: market research reports

Research & Development market research reports and industry analysis

Analytical Tool - Colorectal Cancer 4/22/2013 \| published by: BioSeeker Group AB ... map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies ... \| read more...	$11,625.00
Alpha6 Beta4 Integrin Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... 321 Alpha6Beta4 integrin pathway targeting drugs in 1113 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 134 drugs. ... \| read more...	$5,621.25
Antibodies in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... for the second wave in the lucrative field of therapeutic antibodies. There are today 303 companies plus partners developing 598 antibody drugs in 1408 developmental projects in cancer. In addition, there are 6 suspended drugs ... \| read more...	$5,621.25
Biologicals in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... developing 1460 biological drugs in 3194 developmental projects in cancer. In addition, there are 25 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 868 drugs. Biologicals In ... \| read more...	$9,371.25
B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... leads to activation of several non-receptor tyrosine kinases including those of the Src, Tec and Syk family of kinases. Downstream messengers include DAG, IP3, MAPK/ERK and JNK signaling modules. There are today 207 companies plus ... \| read more...	$5,621.25
Cellular Therapy in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... the accumulated number of ceased drugs over the last years amount to another 62 drugs. Cellular Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of ... \| read more...	$3,746.25
Bladder Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... treated early, the 5 year survival rate is 94%. There are today 98 companies plus partners developing 111 drugs targeting bladder cancer in development. In addition, there are 3 suspended drugs and the accumulated number ... \| read more...	$3,746.25
Brain Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... deadly diseases in the developed world. While primary brain tumors are relatively rare, the chances of survival for patients with the disease are very low, even with the best treatment options currently available. There are ... \| read more...	$5,621.25
Cancer Stem Cells Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... development and cancer drugs which are inhibitors of the Hedgehog, Notch, and WNT Pathway. These developmental pathways are frequently activated in neoplasms, and particularly in the rare subpopulation of cancer stem cells. There are today ... \| read more...	$5,621.25
Androgen Receptor Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... developmental projects in cancer. In addition, there are 4 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 196 drugs. Androgen Receptor Signaling Pathway In Oncology Drug Pipeline ... \| read more...	$5,621.25
Breast Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... and metastatic setting, the overall survival remains below five years. There are today 359 companies plus partners developing 497 drugs targeting breast cancer in development. In addition, there are 9 suspended drugs and the accumulated ... \| read more...	$5,621.25
Cytokine Therapy in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... accumulated number of ceased drugs over the last years amount to another 7 drugs. Cytokine Therapy In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. ... \| read more...	$3,746.25
Hedgehog Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... today 55 companies plus partners developing 47 Hedgehog pathway targeting drugs in 225 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years ... \| read more...	$1,871.25
IL-1 Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... the MAPK signaling module and activate NFkB, they are synergistic and complement each other's activity. There are today 79 companies plus partners developing 71 IL-1 pathway targeting drugs in 282 developmental projects in cancer. In ... \| read more...	$3,746.25
IL-5 Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... 514 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 48 drugs. Il-5 Signaling Pathway In Oncology Drug Pipeline ... \| read more...	$5,621.25
IL-7 Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 19 drugs. Il-7 Signaling Pathway In Oncology Drug Pipeline Update lists ... \| read more...	$1,871.25
IL-9 Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 20 drugs. Il-9 Signaling Pathway In Oncology Drug Pipeline Update ... \| read more...	$3,746.25
Kit Receptor Signaling Pathway in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... with several human malignancies include leukemias, gastrointestinal stromal tumors and mastocytomas. There are today 160 companies plus partners developing 248 Kit receptor pathway targeting drugs in 970 developmental projects in cancer. In addition, there are ... \| read more...	$5,621.25
Liver Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... drugs over the last years amount to another 49 drugs. Liver Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 154 ... \| read more...	$3,746.25
Lymphoma Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... in cancer. In addition, there are 4 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 85 drugs. Lymphoma Drug Pipeline Update lists all drugs and gives you ... \| read more...	$5,621.25
Melanoma Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... R&D, five-year survival of advanced patients remains below 20%. There are today 251 companies plus partners developing 296 drugs targeting melanoma in development. In addition, there are 3 suspended drugs and the accumulated number of ... \| read more...	$5,621.25
Nucleic Acid Therapies in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... are today 221 companies plus partners developing 256 nucleic acid therapy drugs in 567 developmental projects in cancer. In addition, there are 7 suspended drugs and the accumulated number of ceased drugs over the last ... \| read more...	$5,621.25
Pancreatic Cancer Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... drugs over the last years amount to another 101 drugs. Pancreatic Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 235 ... \| read more...	$5,621.25
Protein Kinase Inhibitors in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... three successful drugs are just the top of an emerging line of therapy. Given the fact that they all target tyrosine kinases and that kinase mutations can cause patients to become resistant to these drugs, ... \| read more...	$5,621.25
Proteins in Oncology Drug Pipeline Update 2013 4/22/2013 \| published by: BioSeeker Group AB ... 583 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 168 drugs. Proteins In Oncology Drug Pipeline Update lists ... \| read more...	$5,621.25

< prev 1 2 3 4 5 6 7 8 9 10 next >